Sergey L. Khatsko

TL;DR: Recent developments in zebrafish genetics and small molecule screening are summarized, which markedly enhance the disease modelling and the discovery of novel drug targets.

TL;DR: It is suggested that novel antidepressants can be developed based on targeting microglia-, PUFAs-, glucocorticoid- and gut microbiota-mediated cellular pathways, and a wider application of novel model organisms, such as zebrafish, in studying shared, evolutionarily conserved neuro-immune mechanisms of depression.

TL;DR: Zebrafish high sensitivity to acute effects of amitriptyline can help improve the understanding of psychopharmacological profiles of this compound and the related CNS drugs, and contributes further to the development of aquatic experimental models of human toxidromes.

TL;DR: It is argued that zebrafish-based models represent an excellent translational tool to understand aggressive behaviors and related pathobiological brain mechanisms and their genetic, pharmacological and environmental modulation.

TL;DR: Given the growing clinical importance of anti-M deliriant hallucinogens, the use and abuse, clinical importance, and the growing value in preclinical (experimental) animal models relevant to modeling CNS functions and dysfunctions are discussed.